ClinicalTrials.gg
CompletedNCT00806221Updated Jul 11, 2017Results posted

An Open-Label Study Investigating the Effects of Early Skin Barrier Protection on the Development of Atopic Dermatitis

A Phase 2 interventional study of emollient (Cetaphil cream) in Atopic Dermatitis, sponsored by Oregon Health and Science University. Completed at 1 site in United States. Open to participants aged Up to 1 Month. Per ClinicalTrials.gov, last updated 2017-07-11.

Sponsored by Oregon Health and Science University · Phase 2, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
22
Allocation
Not applicable
Ages
Up to 1 Month
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 639 studies in Dermatitis, Atopic with a site in United States — 78 open to participants now, 117 under way, 18 of them phase 3. Dermatitis, Atopic · United States.

Enrollment
447th of 544
22 · median 96
Started
2006
with 8 others
Phase 2
202 of 639
18 open now
Registered
54th of 639
by date

Among the 639 studies in Dermatitis, Atopic with a site in United States, this one is the 447th largest by enrollment of the 544 interventional ones that give a count, is one of 9 that started in 2006, is one of 202 in phase 2, and was the 54th registered.

Dermatitis, Atopic

1,596 studies on the registry are indexed under Dermatitis, Atopic; 289 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

78 of the 639 studies in Dermatitis, Atopic with a site in United States are open now. Recruiting first, the newest first:

73 more — sign in →

All 78 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 195 Dermatitis, Atopic studies recruiting now, 84 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.

This study: Up to 1 Month · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 639 studies in Dermatitis, Atopic with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether early use of a bland emollient in newborns, prior to the clinical signs of skin disease, will delay the onset or prevent the development of atopic dermatitis.

Read the detailed description

All neonates will be treated with Cetaphil cream starting within 1 week of birth. All neonates enrolled will have an increased risk of developing atopic dermatitis because they have a family history of either asthma, hay fever, or atopic dermatitis. These neonates will then be followed for 2 years for the signs and symptoms of atopic dermatitis.

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

Keywords

  • Atopic Dermatitis
  • Prevention
  • Skin Barrier
04

Who can participate

Ages eligible
Up to 1 Month
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • at least one parent diagnosed with Atopic Dermatitis
  • one parent or sibling with hayfever or asthma

Exclusion criteria

Exclusion Criteria:

  • newborns with dermatitis at birth
  • newborns born greater than four weeks prematurely
  • newborns with medical problems necessitating prolonged hospitalization
  • newborns diagnosed with any immune deficiency syndrome
05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    Emollient

    Skin barrier protection from birth

    Drug: emollient (Cetaphil cream)

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of Skin Irritation

    Time frame: 1 and 2 year time points

  2. Incidence of Skin Infection

    Time frame: 1 and 2 year timepoints

  3. Compliance With Protocol

    Time frame: over two years

Secondary outcomes

  1. Development of Eczema

    Time frame: 1 and 2 year time points

07

Results

Posted Jul 11, 2017

Participant flow

Participant flow — Overall Study
MilestoneEmollient
Started22
Completed20
Not completed2

Outcome measures

PrimaryIncidence of Skin Irritation
Time frame:
1 and 2 year time points
Reported as:
Count of participants · Participants
Incidence of Skin Irritation
ParticipantsEmollient
Incidence of Skin Irritation0
PrimaryIncidence of Skin Infection
Time frame:
1 and 2 year timepoints
Reported as:
Count of participants · Participants
Incidence of Skin Infection
ParticipantsEmollient
Incidence of Skin Infection0
PrimaryCompliance With Protocol
Time frame:
over two years
Reported as:
Number · participants
Compliance With Protocol
participantsEmollient
Compliance With Protocol20
SecondaryDevelopment of Eczema
Time frame:
1 and 2 year time points
Reported as:
Count of participants · Participants
Development of Eczema
ParticipantsEmollient
Development of Eczema5

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Emollient—0/22 (0%)0/22 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Emollient
<=18 years22
Between 18 and 65 years0
>=65 years0
Sex/Gender, Customized
Sex/Gender, Customized(participants)Emollient
gender/sex was not recorded22
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Emollient
non-Hispanic Caucasian16
Hispanic Caucasian2
Asian2
African American2
Region of Enrollment
Region of Enrollment(participants)Emollient
United States22
08

Study locations

1 site
  • Oregon Health & Science University, Department of Dermatology
    Portland, Oregon 97239, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2006, a primary completion of Nov 2008 and a completion of Nov 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2017, 8 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 8, 2008
First posted
Dec 10, 2008
Start
Nov 2006
Primary completionActual
Nov 2008
CompletionActual
Nov 2009
Results first posted
Jul 11, 2017
Last update
Jul 11, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 11, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00806221
Collaborators
Galderma R&D
Responsible party
Eric Simpson (Professor, Dermatology, Oregon Health and Science University) — Principal investigator
First posted
Dec 10, 2008
Start date
Nov 2006
Primary completion
Nov 2008
Completion
Nov 2009
Results posted
Jul 11, 2017
Last update
Jul 11, 2017

Study contacts

Eric Simpson, MD
principal investigator · Oregon Health and Science University

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cetyl alcohol, propylene glycol, sodium lauryl sulfate non-lipid cleansing lotion

Start the discussion